

Losartan

Catalog No: **tcsc2116**



Available Sizes

Size: 1g

Size: 5g



Specifications

CAS No:

114798-26-4

Formula:

$C_{22}H_{23}ClN_6O$

Pathway:

GPCR/G Protein

Target:

Angiotensin Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (236.46 mM)

Alternative Names:

DuP-753

Observed Molecular Weight:

422.91


Product Description

Losartan is an **angiotensin II receptor** antagonist, competing with the binding of angiotensin II to AT1 receptors with **IC₅₀** of 20 nM.

IC50 & Target: IC50: 20 nM (angiotensin II)

In Vitro: Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC_{50}) is 20 nM^[1]. Losartan (40 μ M) affects I_{SC} but prevents the effect of ANGII on I_{SC} ^[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone^[3].

In Vivo: Losartan (0.6 g/L, p.o.) -treated *Fbn1*^{C1039G/+} mice show a reduction in distal airspace caliber relative to placebo-treated *Fbn1*^{C1039G/+} animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF- β signaling in the aortic wall of *Fbn1*^{C1039G/+} mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics^[4]. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged^[5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!